Why the market pays for medicines you take less often

Inclisiran made the point plainly. A cholesterol-lowering therapy dosed roughly twice a year, rather than daily, was valuable enough that Novartis paid billions to bring it in. The clinical logic is adherence: a treatment people actually stay on works better in the real world. The commercial logic follows: durable, infrequent dosing is a franchise, not a refill.

The same principle is reshaping how partners value newer modalities. If a therapy can be given rarely and keep working, that durability is not a footnote in the model, it is a driver of the model. When we build a value case, that is one of the first things we test.

Work with Modulus

Have a program worth de-risking?

See how we work with inventors →

Filling a pipeline gap?

Talk to us →